Moderna (MRNA) Stock Forecast & Price Target

Moderna is supported by a validated mRNA platform that has moved from a 2010 founding and 2018 IPO to a broad pipeline of 25 clinical candidates as of March 2026, spanning infectious disease, oncology, cardiovascular disease, and rare genetic diseases. Its outlook is strengthened by positive Phase III INTerpath-001 data showing intismeran plus KEYTRUDA improved RFS by 42% and DMFS by 38%, while the 50/50 profit share with Merck and proof-of-mechanism in other tumors expand the franchise’s long-term commercial reach. Financially, Moderna also has multiple vaccine revenue drivers, including updated COVID and seasonal flu products, projected 11% revenue growth to $2.15 billion this year, about $8.52 billion in proforma cash, and an expectation of regaining profitability in 2028.

Moderna is a commercial-stage biotech whose investment case depends heavily on the continued success of its mRNA platform, but the technology remains clinically and commercially unproven across most of its pipeline beyond the covid vaccine authorized in the United States in December 2020. With 25 mRNA development candidates in clinical studies as of March 2026 across infectious disease, oncology, cardiovascular disease, and rare genetic diseases, execution risk is high because many programs could fail in the clinic or not win approval. Fundamentally, the bearish view rests on the possibility that products do not reach sales forecasts while development and commercialization spending exceeds budget, pressuring profitability and limiting the company’s ability to convert its broad pipeline into durable cash generation.